OncoMatch/Clinical Trials/NCT05940532
A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC
Is NCT05940532 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Sugemalimab and Chemotherapy for carcinoma, non-small-cell lung.
Treatment: Sugemalimab and Chemotherapy — The goal of this phase II, open-label, single-arm study is to evaluate the efficacy and safety of induction immunotherapy and chemotherapy followed by the multidisciplinary team (MDT)-guided radiotherapy or surgery in unresectable, stage III non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Excluded: ALK fusion
Excluded: EGFR mutation
Disease stage
Required: Stage III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-tumor therapy
Previous systemic anti-tumor therapy including immune checkpoint inhibitors for NSCLC
Cannot have received: thoracic radiotherapy
Previous thoracic radiotherapy
Lab requirements
Blood counts
Major organ function is basically normal
Kidney function
Major organ function is basically normal
Liver function
Major organ function is basically normal
Major organ function is basically normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify